Results 31 to 40 of about 13,217 (287)

Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis: A case report

Journal of Medical Case Reports, 2011
Introduction Osteonecrosis of the jaw is a serious side effect in patients receiving nitrogen-containing bisphosphonates intravenously due to malignant diseases.
Ehrenfeld Michael, Sotlar Karl, Otto Sven, Pautke Christoph   +3 more
doaj   +1 more source

Alterations of bone proteins in medication-related osteonecrosis of the jaw. [PDF]

Eur J Oral Sci
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Schubert A, Brockmeyer P, Kauffmann P, Wiegel J, Lautenbacher F, Miosge N, Schminke B.   +6 more
europepmc   +2 more sources

Therapeutic effect of fluvastatin on medication-related osteonecrosis of the jaw.

The Journal of Periodontology, 2021
BACKGROUND Refractory jaw osteonecrosis that occurs in osteoporotic or cancer patients treated with bisphosphonates is called medication-related osteonecrosis of the jaw but its underlying mechanism is unclear.
Koma Sanda, Y. Ayukawa, Noriyuki Yasunami, Naomi Adachi, A. Furuhashi, Mikio Imai, Ken Matsunaka, K. Koyano   +7 more
semanticscholar   +1 more source

Bisphosphonates and Osteonecrosis of Jaws

Journal of Indian Academy of Oral Medicine and Radiology, 2012
Bisphosphonates are used to treat osteoporosis. Paget disease of bone and other metabolic bone diseases, multiple myeloma, and skeletal events associated with metastatic neoplasms- In 2003, the first reports describing osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonates were published.
Geetha Vijay, Vijay Raghavan
openaire   +2 more sources

Mesenchymal stem cells in the treatment of osteonecrosis of the jaw

Journal of the Korean Association of Oral and Maxillofacial Surgeons, 2021
Medication-related osteonecrosis of the jaw (MRONJ) has recently associated to the increase in antiresorptive and anti-angiogenic drugs prescriptions in the treatment of oncologic and osteoporotic patients. The physiopathogenesis of MRONJ remains unclear
G. Nifosí, Lorenzo Nifosì, Antonio Fabrizio Nifosì   +2 more
semanticscholar   +1 more source

Osteonecrosis of the jaw in a patient under treatment of osteoporosis with oral bisphosphonate

Autopsy and Case Reports, 2021
Although uncommon in patients under oral therapy, bisphosphonate-related osteonecrosis of the jaw (BRONJ) can be a very severe issue. Early intervention with surgical resection should be the preferable method of treating any stage of the disease ...
Marília A. Figueiredo, Frederico Buhatem Medeiros, Karem López Ortega   +2 more
doaj  

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

Dentistry Journal, 2018
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients.
Vittorio Fusco, Giuseppina Campisi, Paul de Boissieu, Federico Monaco, Anna Baraldi, Gianmauro Numico, Alberto Bedogni   +6 more
doaj   +1 more source

A critical assessment of the medication-related osteonecrosis of the jaw classification in stage I patients: a retrospective analysis

Journal of the Korean Association of Oral and Maxillofacial Surgeons, 2021
Objectives It is unclear whether the extent of intraoral mucosa defects in patients with medication-related osteonecrosis of the jaw indicates disease severity.
O. Ristow, Lena Hürtgen, J. Moratin, Maximilian Smielowski, C. Freudlsperger, M. Engel, J. Hoffmann, T. Rückschloss   +7 more
semanticscholar   +1 more source

OSTEONECROSIS OF THE JAW

The Journal of the American Dental Association, 2011
The paper concerns osteonecrosis of the jaw (ONJ). It is a rare but serious clinical condition. It can develop in patients treated in oncologic doses with bisphosphonates but also with denosumab. In osteoporosis ONJ seems to be very rare. Definition, pathogenesis, risk factors, prevention and treatment, and the frequency of ONJ are presented.
  +7 more sources

The establishment of a bisphosphonate⁃related osteonecrosis of the jaw rat model

口腔疾病防治, 2017
With the wide use of bisphosphonates in bone diseases such as osteoporosis and bone metastases of ma⁃ lignant tumors, bisphosphonate⁃related osteonecrosis of the jaw has gained widely attention as a severe side effect. Ani⁃ mal model is a useful way to
LIU Jie, TANG Hua
doaj   +1 more source